[{"address1": "345 Park Avenue South", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "212-547-9879", "website": "https://www.lexeotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.", "fullTimeEmployees": 58, "companyOfficers": [{"maxAge": 1, "name": "Mr. R. Nolan Townsend", "age": 42, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 864335, "exercisedValue": 0, "unexercisedValue": 6398299}, {"maxAge": 1, "name": "Dr. Eric  Adler M.D.", "age": 49, "title": "Chief Medical Officer & Head of Research", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 623400, "exercisedValue": 0, "unexercisedValue": 586874}, {"maxAge": 1, "name": "Ms. Jenny R. Robertson J.D.", "age": 48, "title": "Chief Business & Legal Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 617900, "exercisedValue": 0, "unexercisedValue": 94692}, {"maxAge": 1, "name": "Dr. Ronald G. Crystal M.D.", "title": "Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rand  Monaghan", "title": "Vice President of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jose Manuel Otero Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sandi See Tai M.D.", "age": 52, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  McHenry", "title": "VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.09, "open": 11.1, "dayLow": 10.9, "dayHigh": 11.356, "regularMarketPreviousClose": 11.09, "regularMarketOpen": 11.1, "regularMarketDayLow": 10.9, "regularMarketDayHigh": 11.356, "forwardPE": -3.7550335, "volume": 265755, "regularMarketVolume": 265755, "averageVolume": 255146, "averageVolume10days": 644224, "averageDailyVolume10Day": 644224, "bid": 11.13, "ask": 11.32, "bidSize": 100, "askSize": 200, "marketCap": 368657888, "fiftyTwoWeekLow": 9.0, "fiftyTwoWeekHigh": 22.33, "fiftyDayAverage": 15.5358, "twoHundredDayAverage": 14.463441, "currency": "USD", "enterpriseValue": 184834368, "floatShares": 19447635, "sharesOutstanding": 32945300, "sharesShort": 775621, "sharesShortPriorMonth": 542854, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0235, "heldPercentInsiders": 0.00489, "heldPercentInstitutions": 0.84476, "shortRatio": 3.57, "shortPercentOfFloat": 0.026400002, "impliedSharesOutstanding": 32945300, "bookValue": 5.553, "priceToBook": 2.015127, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -69419000, "trailingEps": -2.11, "forwardEps": -2.98, "enterpriseToEbitda": -2.57, "52WeekChange": 0.113432884, "SandP52WeekChange": 0.2086575, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "LXEO", "underlyingSymbol": "LXEO", "shortName": "Lexeo Therapeutics, Inc.", "longName": "Lexeo Therapeutics, Inc.", "firstTradeDateEpochUtc": 1699018200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ab1fdece-ecd1-3551-bd81-6134d29606b5", "messageBoardId": "finmb_625814286", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.19, "targetHighPrice": 28.0, "targetLowPrice": 20.0, "targetMeanPrice": 22.86, "targetMedianPrice": 22.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 195060000, "totalCashPerShare": 5.921, "ebitda": -71909000, "totalDebt": 11236000, "quickRatio": 9.018, "currentRatio": 9.158, "debtToEquity": 6.142, "returnOnEquity": -0.5444, "operatingCashflow": -55989000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-22"}]